Related Experiment Video
Updated: May 16, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
METTL3, an Independent Adverse Prognostic Factor for AML, Promotes the Development of AML by Modulating the
Yuqian Tang1, Xiaoyan Liu1,2, Wu Ye1
1Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Background:
m6A represents a prevalent epigenetic modification of mammalian mRNAs. Studies have demonstrated that m6A RNA methylation-modifying enzymes play crucial roles in the onset and progression of AML. However, their clinical relevance remains undefined, and the mechanisms underlying their modulation of AML have yet to be elucidated.
Results:
The expression levels of the m6A RNA-modifying enzymes METTL3, METTL14, WTAP, FTO and ALKBH5 were elevated in AML patients. METTL3-positive AML is often accompanied by DNMT3A mutations and is also an independent poor prognostic factor for AML patients. Following METTL3 knockdown, we observed a decrease in the m6A level of the mitochondrial oxidative stress gene PGC-1α in K562 and MV4-11 cells. We analyzed the expression levels of PGC-1α and METTL3 mRNA in 105 patients with primary AML. The expression levels of PGC-1α and METTL3 mRNA were positively correlated. Similar to METTL3 knockdown, PGC-1α gene knockdown resulted in increased phosphorylation of the key signaling molecules P38, c-Jun and ERK1/2 in the MAPK signaling pathway, and decreased mRNA levels of SOD1, GPX1, catalase and UCP2 in the antioxidant system of K562 cells. Analysis of the TCGA and GSE13159 datasets, along with samples from West China Hospital, revealed that patients exhibiting high PGC-1α expression had a poor prognosis.
Conclusion:
The m6A methylation-modifying enzyme METTL3 is an independent prognostic factor for poor prognosis in AML patients. PGC-1α is a downstream signaling molecule of METTL3, and METTL3 affects its expression by regulating the m6A level of PGC-1α. PGC-1α acts as an oncogene in AML by affecting the MAPK pathway and antioxidant system.
Insights
The m6A RNA-modifying enzyme METTL3 is linked to poor prognosis in acute myeloid leukemia (AML). METTL3 influences the PGC-1α oncogene, impacting MAPK signaling and antioxidant systems in AML progression.
Area of Science:
- Epigenetics
- Molecular Biology
- Oncology
Background:
- m6A is a key mRNA modification in mammals.
- m6A enzymes are implicated in acute myeloid leukemia (AML) but their clinical relevance and mechanisms are unclear.
Purpose of the Study:
- To define the clinical relevance of m6A RNA-modifying enzymes in AML.
- To elucidate the mechanisms by which these enzymes modulate AML.
Main Methods:
- Quantified expression of METTL3, METTL14, WTAP, FTO, and ALKBH5 in AML patients.
- Performed METTL3 and PGC-1α knockdown experiments in AML cell lines (K562, MV4-11).
- Analyzed MAPK signaling pathway and antioxidant system gene expression.
- Correlated PGC-1α and METTL3 mRNA levels with patient prognosis using TCGA and GSE13159 datasets.
Main Results:
- Elevated expression of m6A enzymes, including METTL3, was observed in AML patients.
- METTL3 expression correlated with DNMT3A mutations and predicted poor prognosis.
- METTL3 knockdown decreased m6A levels of PGC-1α, a mitochondrial oxidative stress gene.
- PGC-1α knockdown affected MAPK signaling and antioxidant genes, and high PGC-1α expression indicated poor prognosis.
Conclusions:
- METTL3 is an independent prognostic factor for poor outcomes in AML.
- METTL3 regulates PGC-1α expression via m6A modification.
- PGC-1α functions as an oncogene in AML by influencing the MAPK pathway and antioxidant system.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle
MAPK Signaling Cascades
Differentiation of Common Myeloid Progenitor Cells

